ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Bought by Swiss National Bank

Swiss National Bank grew its holdings in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 6.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 458,400 shares of the biotechnology company's stock after purchasing an additional 28,500 shares during the quarter. Swiss National Bank owned about 0.19% of ADMA Biologics worth $7,862,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ADMA. Larson Financial Group LLC acquired a new position in shares of ADMA Biologics during the 3rd quarter valued at about $31,000. GAMMA Investing LLC boosted its holdings in ADMA Biologics by 106.6% in the 4th quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock valued at $32,000 after purchasing an additional 967 shares during the last quarter. National Bank of Canada FI purchased a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $35,000. Vision Financial Markets LLC acquired a new stake in shares of ADMA Biologics during the 4th quarter worth approximately $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in shares of ADMA Biologics during the 3rd quarter worth approximately $62,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a report on Tuesday, March 4th.

Remove Ads

ADMA Biologics Trading Down 0.5 %

ADMA stock traded down $0.10 during mid-day trading on Tuesday, hitting $20.22. 2,401,540 shares of the company were exchanged, compared to its average volume of 3,368,313. ADMA Biologics, Inc. has a 12-month low of $5.90 and a 12-month high of $23.64. The firm has a market capitalization of $4.78 billion, a P/E ratio of 72.21 and a beta of 0.60. The business has a fifty day simple moving average of $16.91 and a 200-day simple moving average of $18.10. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.